abstract |
The invention relates to the use of glucagon-like peptide-1 (GLP-1) incretin hormones and glucose-dependent insulinotropic peptide (GIP) and the analogues thereof, in particular analogues resistant to dipeptidyl peptidase IV, in the treatment of osteoarthritis, in particular to inhibit or slow down the destruction of cartilage. |